Table 4.
Changes of LDAEP and CGI-S after medication
| Variable | Sample with medication (n = 15) | ||
|---|---|---|---|
|
| |||
| Mean ± SD | Range | pvalue | |
| Age | 9.33 ± 1.8 | 6 to 12 | |
| Total IQ | 114 ± 13.6 | 86 to 134 | |
| Total ARS score | 26.3 ± 11.34 | 12 to 50 | |
| Dose of MPH (mg) | 38.3 ± 12.5 | 18 to 63 | |
| CGI-S | |||
| CGI-S_baseline | 5.41 ± 1.12 | 4 to 7 | Z = −3.332 |
| CGI-S_after MPH trial | 3.27 ± 0.88 | 1 to 3 | p= 0.001 |
| LDAEP | |||
| LDAEP_baseline | 1.02 ± 1.13 | −0.14 to 4.32 | Z = −1.988 |
| LDAEP_after MPH trial | 0.63 ± 1.17 | −0.81 to 3.52 | p= 0.047 |
MPH, methylphenidate; LDAEP, loudness dependence of the auditory evoked potential; ADHD, attention deficit hyperactivity disorder; SD, standard deviation; ARS, ADHD rating scale; IQ, intellectual quotient; CGI-S, clinical global impression severity.
Wilcoxon signed-rank test was conducted.